🇺🇸 FDA
Pipeline program

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

JSVCT088

Phase 1 mab completed

Quick answer

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for COVID-19 is a Phase 1 program (mab) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Indication
COVID-19
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials